These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
251 related items for PubMed ID: 18088500
1. Dosage plan of a flurbiprofen injection product using inhibition of protein binding by lipid emulsion in rats. Ogata K, Takamura N, Tokunaga J, Kawai K, Arimori K, Higuchi S. J Pharm Pharmacol; 2008 Jan; 60(1):15-20. PubMed ID: 18088500 [Abstract] [Full Text] [Related]
2. A novel injection strategy of flurbiprofen axetil by inhibiting protein binding with 6-methoxy-2-naphthylacetic acid. Ogata K, Takamura N, Tokunaga J, Ikeda T, Setoguchi N, Tanda K, Yamasaki T, Nishio T, Kawai K. Eur J Drug Metab Pharmacokinet; 2016 Apr; 41(2):179-86. PubMed ID: 25537338 [Abstract] [Full Text] [Related]
3. Stereoselective pharmacokinetics of flurbiprofen and formation of covalent adducts with plasma protein in adjuvant-induced arthritic rats. Nagao T, Tanino T, Iwaki M. Chirality; 2003 May 15; 15(5):423-8. PubMed ID: 12692887 [Abstract] [Full Text] [Related]
5. A rabbit ear flap perfusion experiment to evaluate the percutaneous absorption of drugs. Seki T, Hosoya O, Yamazaki T, Sato T, Saso Y, Juni K, Morimoto K. Int J Pharm; 2004 May 19; 276(1-2):29-40. PubMed ID: 15113611 [Abstract] [Full Text] [Related]
9. Triplet excited States as chiral reporters for the binding of drugs to transport proteins. Jiménez MC, Miranda MA, Vayá I. J Am Chem Soc; 2005 Jul 27; 127(29):10134-5. PubMed ID: 16028901 [Abstract] [Full Text] [Related]
12. Binding characteristics of KNI-272 to plasma proteins, a new potent tripeptide HIV protease inhibitor. Kiriyama A, Nishiura T, Ishino M, Yamamoto Y, Ogita I, Kiso Y, Takada K. Biopharm Drug Dispos; 1996 Dec 27; 17(9):739-51. PubMed ID: 8968527 [Abstract] [Full Text] [Related]
13. Characterization of drug-protein binding process by employing equilibrium sampling through hollow-fiber supported liquid membrane and Bjerrum and Scatchard plots. Barri T, Trtić-Petrović T, Karlsson M, Jönsson JA. J Pharm Biomed Anal; 2008 Sep 10; 48(1):49-56. PubMed ID: 18565712 [Abstract] [Full Text] [Related]
14. Nanostructured lipid carriers-based flurbiprofen gel after topical administration: acute skin irritation, pharmacodynamics, and percutaneous absorption mechanism. Song A, Su Z, Li S, Han F. Drug Dev Ind Pharm; 2015 Sep 10; 41(9):1488-92. PubMed ID: 25231972 [Abstract] [Full Text] [Related]
18. Absorption kinetics of flurbiprofen axetil microspheres in cerebrospinal fluid: A pilot study . Zhang H, Gu J, Feng Y, An H. Int J Clin Pharmacol Ther; 2017 Nov 10; 55(11):875-880. PubMed ID: 28956529 [Abstract] [Full Text] [Related]
19. Improvement in bioavailability of transdermally applied flurbiprofen using tulsi (Ocimum sanctum) and turpentine oil. Charoo NA, Shamsher AA, Kohli K, Pillai K, Rahman Z. Colloids Surf B Biointerfaces; 2008 Sep 01; 65(2):300-7. PubMed ID: 18579348 [Abstract] [Full Text] [Related]
20. Excised porcine skin experimental systems to validate quantitative microdialysis methods for determination of drugs in skin after topical application. Seki T, Wang A, Yuan D, Saso Y, Hosoya O, Chono S, Morimoto K. J Control Release; 2004 Nov 24; 100(2):181-9. PubMed ID: 15544866 [Abstract] [Full Text] [Related] Page: [Next] [New Search]